Pretreatment lactate dehydrogenase (LDH), tumor mutation burden (TMB), and tumor cell PD-1 ligand (PDL1) expression are thought to correlate with immunotherapy responses and treatment outcome. The gene discussed is CD274; the disease is neoplasm.